神经节苷脂联合丹参酮治疗急性脑梗死患者的疗效观察

The effects of ganglioside GM1 combined with sodium tanshinone sulphonate IIA in treating acute cerebral infarction

目的观察神经节苷脂联合丹参酮对急性脑梗死患者的治疗效果。方法急性脑梗死患者86例,按病例对照研究的方法分组,对照组43例,以丹参酮注射液30 mL+5%葡萄糖注射液250 mL静脉滴注,1次/d,共14 d;联合治疗组43例,在丹参酮治疗基础上联合以神经节苷脂80 mg+5%葡萄糖注射液250 mL静脉滴注,1次/d,共14 d。两组基础用药治疗相同。比较两组患者于治疗前、后神经功能缺损程度(NIHSS)及日常生活活动量(ADL)评分,并进行疗效评定。结果联合治疗组在治疗后14 d NIHSS评分及ADL评分与对照组相比,差异有统计学意义(P<0.05);治疗组临床疗效明显优于对照组(P<0.05),其神经功能缺损程度明显改善,日常生活能力明显提高。结论神经节苷脂联合丹参酮能更好地改善急性脑梗死患者的预后,降低患者的神经功能的缺损程度。

Objective To observe the effects of ganglioside GM1 combined with sodium tanshinone sulpho-nate IIA in the treatment of acute cerebral infarction（ACI）.Mehtods 86 cases with ACI were randomly divided in-to two groups.43 cases in the control group were treated with sodium tanshinone sulphonate IIA 30 mL and 5% GS 250 ml iv gtt,qd for 14 days.43 cases in the combined treatment group were treated with GM1 80 mg and 5%GS 250 mL iv gtt,qd for 14 days;as w ell as sodium tanshinone sulphonate IIA 30 mL and 5% GS 250 mL iv gtt,qd for 14 days.The conventional treatments in two groups were the same.The neurological impairment scores（NIHSS）and ac-tivity of daily living（ADL）scale were evaluated and compared before and after treatmen.Results In combined treat-ment group,there were significant differences in NIHSS and ADL between treatment group and control group after 14 days treatment（P〈0.05）.The clinical curative rate in combined treatment group was significantly higher than that in control group（P〈0.05）.Both the neurological impairment score and capability for daily living improved obviously. Conclusion Ganglioside GM 1 combined with sodium tanshinone sulphonate IIA can improve the prognosis of the patients with ACI preferably and lighten the neural function deficience.